Mallinckrodt — Debt Investor Presentation (October 2025)
25 slides from Mallinckrodt's debt investor presentation, Oct 6, 2025
Slide 1: Lender Presentation October 2025
Lender Presentation October 2025
Slide 2: Information Regarding Forward-Looking Statements
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Information Regarding Forward - Looking Statements 2 Mallinckrodt - Endo Statements in this presentation regarding the businesses of Mallinckrodt plc and its subsidiaries, including Par Health (coll ect ively, “Mallinckrodt”) and
Slide 3: Non-GAAP Financial Measures
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Non - GAAP Financial Measures 3 Mallinckrodt - Endo To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this pr esentation includes certain financial informatio
Slide 4: Introduction to Today's Speakers
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Introduction to Today’s Speakers 4 Mallinckrodt - Endo Sigurdur (Siggi) Olafsson President and Chief Executive Officer 30+ Years of Experience Prior Experience Christiana Stamoulis President and Chief Financial Officer 30 Years o
Slide 5: Agenda
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Agenda Transaction Overview Mallinckrodt - Endo Overview Branded Business Overview Appendix Mallinckrodt - Endo 5
Slide 6: Transaction Overview
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Transaction Overview 6 01
Slide 7: Overview
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Overview 7 Mallinckrodt - Endo 1 Adj. EBITDA figures exclude Therakos & Endo International Pharmaceuticals; Assumes merger net synergies of $150 million. Inc lu des transaction - related compensation expenses related to the merge
Slide 8: Sources and Uses & Pro Forma Capitalization
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Sources and Uses & Pro Forma Capitalization 8 Mallinckrodt - Endo Note: Adj. EBITDA figures exclude Therakos & Endo International Pharmaceuticals; 1 Assumes merger net synergies of $150 million. Legacy Endo debt, which governs Br
Slide 9: BrandedCo Pro Forma Capitalization
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. BrandedCo Pro Forma Capitalization 9 Mallinckrodt - Endo Note: Adj. EBITDA figures exclude Therakos & Endo International Pharmaceuticals; 1 WholeCo cash represents combined 6/27/2025 cash balances, less minimum merger day cash ba
Slide 10: Summary of Indicative Terms – Endo First Lien Term Loan
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Summary of Indicative Terms – Endo First Lien Term Loan 10 Mallinckrodt - Endo • Endo Finance Holdings LP (f/k/a Endo Finance Holdings, Inc.) (same as existing) Borrower • Endo LP (f/k/a Endo, Inc.) and, subject to certain except
Slide 11: Proposed Transaction Timeline
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Proposed Transaction Timeline 11 Mallinckrodt - Endo October S F T W T M S 4 3 2 1 11 10 9 8 7 6 5 18 17 16 15 14 13 12 25 24 23 22 21 20 19 31 30 29 28 27 26 Key Transaction Date Event Date Announce Transaction & Lender Call Oct
Slide 12: Pro Forma Organizational Structure
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. • Irish parent company (SEC registrant, not currently listed). Outside of both lending groups. • Holding company (formerly known as Endo, Inc.), and parent guarantor of the Endo Senior Secured Notes and Credit Facilities • Issuer
Slide 13: Overview
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Mallinckrodt - Endo Overview 13 02
Slide 14: Overview (Prior to Par Health Separation)
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Mallinckrodt - Endo Overview (Prior to Par Health Separation) 14 Mallinckrodt - Endo Scaled and diversified branded pharmaceuticals portfolio Scaled generics business with a broad product portfolio Increased strategic and financi
Slide 15: Transaction Structure
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Transaction Structure 15 Mallinckrodt - Endo Creating 2 separate entities: 1 A leading, scaled brands business 2 A focused sterile injectables & generics business to be separated post - transaction 1 Combined Company Sterile Inje
Slide 16: 2024A Revenue Mix
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. 15% 14% 8% 26% 13% 13% 11% Transaction Overview 16 Mallinckrodt - Endo 2024A Revenue Mix Brands Business (BrandedCo) Sterile Injectables & Generics Business (Par Health) 1 Combined Company (MergeCo) Endo Mallinckrodt XIAFLEX Othe
Slide 17: Branded Business Will be a Scaled and Diversified Branded Portfolio
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Branded Business Will be a Scaled and Diversified Branded Portfolio… 17 Mallinckrodt - Endo Diversified pharma business of scale led by durable key brands XIAFLEX ® and Acthar ® Gel $1.7bn Pro Forma ‘24A Revenue 1 Enhanced commer
Slide 18: Branded Business Overview
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Branded Business Overview 18 03
Slide 19: Branded Business is a Durable Portfolio Focused on Rare Disease
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Branded Business is a Durable Portfolio Sharing a Focus on Rare Disease Offerings 19 XIAFLEX Product Overview Acthar Product Overview • Only nonsurgical approved product for patients with Peyronie’s Disease and Dupuytren’s contra
Slide 20: Product Innovation Drives Acthar's Return to Growth
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Product Innovation and Strong Business Fundamentals Drive Acthar’s Return to Growth 20 Mallinckrodt - Endo Launch of SelfJect further differentiates Acthar’s offering • Acthar Gel is built on a long - standing legacy of experienc
Slide 21: XIAFLEX Development Pipeline is Anchored by a Durable IP Estate
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. XIAFLEX® Development Pipeline is Anchored by a Durable IP Estate 21 Mallinckrodt - Endo Patients Under Treatment Phase 3 Phase 2 Phase 1 Pre - Clinical Indication ~200,000 Plantar Fibromatosis ~415,000 Plantar Fasciitis ~2.7M adu
Slide 22: Branded Business Financial Performance Over Time
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Branded Business Financial Performance Over Time 22 Key Commentary • Branded Business growth has been driven primarily by growth in Acthar and XIAFLEX® • XIAFLEX®, which had a 14% CAGR from 2015 to 2024, has the opportunity for f
Slide 23: Appendix
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Appendix 23 04
Slide 24: Total Company – Adjusted EBITDA Reconciliation
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. Total Company – Adjusted EBITDA Reconciliation 24 Mallinckrodt - Endo Note: Assumes merger net synergies of $150 million; Adj. EBITDA excludes Therakos & Endo International Pharmaceuticals. Malli nck rodt LTM Adj. EBITDA differs
Slide 25: affiliates. All rights reserved.
© 2025 Mallinckrodt plc or one of its affiliates. All rights reserved. 25
Mallinckrodt — Debt Investor Presentation (October 2025) on 6ix